Loading
A study building a guide to help people decide whether to have a multi-cancer blood test.
MD Anderson decision aid for multi-cancer early detection testing (NCT06870916) is an observational study sponsored by M.D. Anderson Cancer Center. It aims to develop a participant educational aid to support informed decisions about multi-cancer early detection tests.
The registry record, read on 29 October 2026, gives its status as suspended, with an estimated 150 participants, a start on 7 March 2025 and primary completion expected on 1 January 2027.
Shares A mandatory decision aid before any multi-cancer blood test, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/